Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

A practical guide for the generation of model-based virtual clinical trials

Open access
Craig, Morgan, Gevertz, Jana L., Kareva, Irina, Wilkie, Kathleen P. · 2023 · Frontiers in Systems Biology

Abstract

Mathematical modeling has made significant contributions to drug design, development, and optimization. Virtual clinical trials that integrate mathematical models to explore patient heterogeneity and its impact on a variety of therapeutic questions have recently risen in popularity. Here, we outline best practices for creating virtual patients from mathematical models to ultimately implement and execute a virtual clinical trial. In this practical guide, we discuss and provide examples of model design, parameter estimation, parameter sensitivity, model identifiability, and virtual patient cohort creation. Our goal is to help researchers adopt these approaches to further the use of virtual population-based analysis and virtual clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fsysb.2023.1174647

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Schematic of the process to design and implement an in silico clinical trial. The nature of the process is cyclical, with the possibility of steps being revisited as needed.
FIGURE 1 Schematic of the process to design and implement an in silico clinical trial. The nature of the process is cyclical, with the possibility of steps being revisited as needed.CC BY · PubMed Central
FIGURE 2 Illustration of the profile likelihood method. Profile likelihood curves (blue) of (A) a practically identifiable parameter, (B) a structurally non-identifiable parameter, and (C) a structurally identifiable but practically non-identifiable parameter. Thresholds for the 95% confidence intervals are indicated with red dashed lines. (D) Two parametrizations of the model of immunostimulatory oncolytic viruses and dendritic cell injections in (Luo et al., 2022) that have near-identical fits to tumor volume data, yet yield drastically different predictions for post-treatment tumor dynamics.
FIGURE 2 Illustration of the profile likelihood method. Profile likelihood curves (blue) of (A) a practically identifiable parameter, (B) a structurally non-identifiable parameter, and (C) a structurally identifiable but practically non-identifiable parameter. Thresholds for the 95% confidence intervals are indicated with red dashed lines. (D) Two parametrizations of the model of immunostimulatory oncolytic viruses and dendritic cell injections in (Luo et al., 2022) that have near-identical fits to tumor volume data, yet yield drastically different predictions for post-treatment tumor dynamics.CC BY · PubMed Central
FIGURE 3 Example of conducting a virtual clinical trial. (A) Model of oncolytic virotherapy, where uV(t) is the source term of the virus determined by the administration schedule shown in (C) (Wares et al., 2015). (B) Model parameters and initial conditions. (C) Best fit of model to average experimental data when fitting only the parameters and initial conditions specified in (B). (D–F) Profile likelihood curves for the non-fixed parameters. (G) 100 virtual patients that form our virtual population. (H) Virtual clinical trial predicts what percent of virtual patients shrink in response to OV treatment as a function of OV dose [with the protocol fixed as in (C)]. Doses range from experimental dose of 1010 OVs/injection to 90 times the experimental dose.
FIGURE 3 Example of conducting a virtual clinical trial. (A) Model of oncolytic virotherapy, where uV(t) is the source term of the virus determined by the administration schedule shown in (C) (Wares et al., 2015). (B) Model parameters and initial conditions. (C) Best fit of model to average experimental data when fitting only the parameters and initial conditions specified in (B). (D–F) Profile likelihood curves for the non-fixed parameters. (G) 100 virtual patients that form our virtual population. (H) Virtual clinical trial predicts what percent of virtual patients shrink in response to OV treatment as a function of OV dose [with the protocol fixed as in (C)]. Doses range from experimental dose of 1010 OVs/injection to 90 times the experimental dose.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 60 references

Research works printed but not linked: 2

  1. 2022, Project Optimus Reforming the dose optimization and dose selection paradigm in oncology
  2. Mendes, 2001, Modeling large biological systems from functional genomic data: Parameter estimation, Found. Syst. Biol., 2001, 163

Cited by

See all 59

Metadata

Authors
Craig, M., Gevertz, J. L., Kareva, I., & Wilkie, K. P.
Affiliations
  • Centre Hospitalier Universitaire Sainte-Justine (CA)
  • The College of New Jersey (US)
  • EMD Serono, Inc. (United States) (US)
  • Toronto Metropolitan University (CA)
Corresponding author
  • Craig, Morgan
  • Wilkie, Kathleen P.
Venue
Frontiers in Systems Biology
Published
2023-06-16
Volume
3
Pages
1174647-1174647
ISSN
2674-0702 (ISSN-L)
OpenAlex
W4380988248
Cited by
52
References
60
Citations by year
2026: 21 · 2025: 20 · 2024: 10 · 2023: 1
FWCI
10.57
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Systems Biology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Natural Sciences and Engineering Research Council of Canada (RGPIN-2018-04546)
  • Fonds de Recherche du Québec—Santé
Topics
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Keywords
virtual clinical trials, virtual patients, mathematical modeling, patient heterogeneity, parameter estimation, parameter sensitivity analysis, model identifiability, virtual patient cohorts, drug development

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A practical guide for the generation of model-based virtual clinical trials. https://app.cochat.ai/papers/10.3389/fsysb.2023.1174647
The paper
Craig, M., Gevertz, J. L., Kareva, I., & Wilkie, K. P. (2023). A practical guide for the generation of model-based virtual clinical trials. Frontiers in Systems Biology. https://doi.org/10.3389/fsysb.2023.1174647

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.